Engineering a CD123xCD3 bispecific scFv immunofusion for the treatment of leukemia and elimination of leukemia stem cells (Q39323781)

11 September 2017

Engineering a CD123xCD3 bispecific scFv immunofusion for the treatment of leukemia and elimination of leukemia stem cells (English)

1 reference

11 September 2017

1 reference

Shu-Ru Kuo

1

1 reference

PubMed ID

22740616

11 September 2017

Lucas Wong

series ordinal

2

1 reference

PubMed ID

22740616

11 September 2017

Jen-Sing Liu

series ordinal

3

1 reference

11 September 2017

27 June 2012

1 reference

Protein Engineering Design and Selection

11 September 2017

1 reference

11 September 2017

25

1 reference

11 September 2017

10

1 reference

11 September 2017

561-569

1 reference

Monoclonal antibodies for the treatment of acute myeloid leukemia

11 September 2017

1 reference

https://api.crossref.org/works/10.1093%2FPROTEIN%2FGZS040

Chimeric T-cell receptors: new challenges for targeted immunotherapy in hematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FPROTEIN%2FGZS040

Signal transduction, cell cycle regulatory, and anti-apoptotic pathways regulated by IL-3 in hematopoietic cells: possible sites for intervention with anti-neoplastic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FPROTEIN%2FGZS040

Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FPROTEIN%2FGZS040

Strictly target cell-dependent activation of T cells by bispecific single-chain antibody constructs of the BiTE class

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FPROTEIN%2FGZS040

A bispecific diabody directed against prostate-specific membrane antigen and CD3 induces T-cell mediated lysis of prostate cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FPROTEIN%2FGZS040

Bispecific antibodies engage T cells for antitumor immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FPROTEIN%2FGZS040

Design and production of novel tetravalent bispecific antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FPROTEIN%2FGZS040

SEEDbodies: fusion proteins based on strand-exchange engineered domain (SEED) CH3 heterodimers in an Fc analogue platform for asymmetric binders or immunofusions and bispecific antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FPROTEIN%2FGZS040

A stable IgG-like bispecific antibody targeting the epidermal growth factor receptor and the type I insulin-like growth factor receptor demonstrates superior anti-tumor activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FPROTEIN%2FGZS040

Detection of molecular targets on the surface of CD34+/CD38-- stem cells in various myeloid malignancies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FPROTEIN%2FGZS040

Characterization of diphtheria fusion proteins targeted to the human interleukin-3 receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FPROTEIN%2FGZS040

Expression and prognostic value of hemopoietic cytokine receptors in acute myeloid leukemia (AML): implications for future therapeutical strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FPROTEIN%2FGZS040

Nuclear factor-kappaB is constitutively activated in primitive human acute myelogenous leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FPROTEIN%2FGZS040

Selective targeting and potent control of tumor growth using an EphA2/CD3-Bispecific single-chain antibody construct

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FPROTEIN%2FGZS040

Influence of relative binding affinity on efficacy in a panel of anti-CD3 scFv immunotoxins

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FPROTEIN%2FGZS040

Buy buy bispecific antibodies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FPROTEIN%2FGZS040

Human acute myeloid leukemia stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FPROTEIN%2FGZS040

Acute myeloid leukemia originates from a hierarchy of leukemic stem cell classes that differ in self-renewal capacity

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FPROTEIN%2FGZS040

Protein engineering of antibody binding sites: recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in Escherichia coli

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FPROTEIN%2FGZS040

Chemotherapy-resistant human AML stem cells home to and engraft within the bone-marrow endosteal region.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FPROTEIN%2FGZS040

Monoclonal antibody-mediated targeting of CD123, IL-3 receptor alpha chain, eliminates human acute myeloid leukemic stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FPROTEIN%2FGZS040

The interleukin-3 receptor alpha chain is a unique marker for human acute myelogenous leukemia stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FPROTEIN%2FGZS040

Oncogene-dependent engraftment of human myeloid leukemia cells in immunosuppressed mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FPROTEIN%2FGZS040

Stem cell transplants for patients with relapsed/refractory leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FPROTEIN%2FGZS040

Antibody internalization after cell surface antigen binding is critical for immunotoxin development.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FPROTEIN%2FGZS040

A cell initiating human acute myeloid leukaemia after transplantation into SCID mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FPROTEIN%2FGZS040

Application of dual affinity retargeting molecules to achieve optimal redirected T-cell killing of B-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FPROTEIN%2FGZS040

Molecularly targeted therapies in myelodysplastic syndromes and acute myeloid leukemias

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FPROTEIN%2FGZS040

Immunotherapy of lymphoma and leukemia with T-cell engaging BiTE antibody blinatumomab

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FPROTEIN%2FGZS040

The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of acute myelogenous leukemia in adults: an evidence-based review

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FPROTEIN%2FGZS040

Humoral response to catumaxomab correlates with clinical outcome: results of the pivotal phase II/III study in patients with malignant ascites

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FPROTEIN%2FGZS040

Cancer stem cell-directed therapies: recent data from the laboratory and clinic

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FPROTEIN%2FGZS040

Immunophenotypic features of acute myeloid leukemias overexpressing the interleukin 3 receptor alpha chain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FPROTEIN%2FGZS040

The allogeneic graft-versus-cancer effect.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FPROTEIN%2FGZS040

Membrane traffic exploited by protein toxins

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FPROTEIN%2FGZS040

Novel monoclonal antibodies for cancer treatment: the trifunctional antibody catumaxomab (removab).

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FPROTEIN%2FGZS040

Human leukaemic stem cells: a novel target of therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FPROTEIN%2FGZS040

Novel conjugates of single-chain Fv antibody fragments specific for stem cell antigen CD123 mediate potent death of acute myeloid leukaemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FPROTEIN%2FGZS040

Novel therapeutic agents in acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FPROTEIN%2FGZS040

Elevated expression of IL-3Ralpha in acute myelogenous leukemia is associated with enhanced blast proliferation, increased cellularity, and poor prognosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FPROTEIN%2FGZS040

Improved binding of a bivalent single-chain immunotoxin results in increased efficacy for in vivo T-cell depletion

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FPROTEIN%2FGZS040

Induction of apoptosis by tumor cell-targeted toxins

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FPROTEIN%2FGZS040

Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FPROTEIN%2FGZS040

Expression and purification of the recombinant diphtheria fusion toxin DT388IL3 for phase I clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FPROTEIN%2FGZS040

Genetic alteration of a bispecific ligand-directed toxin targeting human CD19 and CD22 receptors resulting in improved efficacy against systemic B cell malignancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FPROTEIN%2FGZS040

High stem cell frequency in acute myeloid leukemia at diagnosis predicts high minimal residual disease and poor survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FPROTEIN%2FGZS040

Cancer stem cells: lessons from leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FPROTEIN%2FGZS040

An improved linker for single-chain Fv with reduced aggregation and enhanced proteolytic stability.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FPROTEIN%2FGZS040

BiTEs: bispecific antibody constructs with unique anti-tumor activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FPROTEIN%2FGZS040

GMP production and characterization of the bivalent anti-human T cell immunotoxin, A-dmDT390-bisFv(UCHT1) for phase I/II clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FPROTEIN%2FGZS040

Expression of interleukin-3 receptor subunits on defined subpopulations of acute myeloid leukemia blasts predicts the cytotoxicity of diphtheria toxin interleukin-3 fusion protein against malignant progenitors that engraft in immunodeficient mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FPROTEIN%2FGZS040

Transcription factors mediating interleukin-3 survival signals

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FPROTEIN%2FGZS040

21 January 2018

Identifiers

DOI

10.1093/PROTEIN/GZS040

1 reference

11 September 2017

1 reference

PubMed ID

22740616